nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ALB—acquired immunodeficiency syndrome	0.21	1	CbGaD
Tacrolimus—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.039	0.0757	CbGbCtD
Tacrolimus—CYP3A7—Delavirdine—acquired immunodeficiency syndrome	0.0232	0.045	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Delavirdine—acquired immunodeficiency syndrome	0.0232	0.045	CbGbCtD
Tacrolimus—CYP3A7—Indinavir—acquired immunodeficiency syndrome	0.02	0.0389	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Indinavir—acquired immunodeficiency syndrome	0.02	0.0389	CbGbCtD
Tacrolimus—CYP3A7—Nelfinavir—acquired immunodeficiency syndrome	0.0195	0.0377	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Nelfinavir—acquired immunodeficiency syndrome	0.0195	0.0377	CbGbCtD
Tacrolimus—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0193	0.0374	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Saquinavir—acquired immunodeficiency syndrome	0.0176	0.0341	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Ritonavir—acquired immunodeficiency syndrome	0.0176	0.0341	CbGbCtD
Tacrolimus—CYP3A7—Ritonavir—acquired immunodeficiency syndrome	0.0176	0.0341	CbGbCtD
Tacrolimus—CYP3A7—Saquinavir—acquired immunodeficiency syndrome	0.0176	0.0341	CbGbCtD
Tacrolimus—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0174	0.0338	CbGbCtD
Tacrolimus—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0174	0.0338	CbGbCtD
Tacrolimus—ALB—Saquinavir—acquired immunodeficiency syndrome	0.0164	0.0319	CbGbCtD
Tacrolimus—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0157	0.0305	CbGbCtD
Tacrolimus—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.015	0.0292	CbGbCtD
Tacrolimus—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0146	0.0283	CbGbCtD
Tacrolimus—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0132	0.0256	CbGbCtD
Tacrolimus—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0132	0.0256	CbGbCtD
Tacrolimus—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0125	0.0243	CbGbCtD
Tacrolimus—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0113	0.022	CbGbCtD
Tacrolimus—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00979	0.019	CbGbCtD
Tacrolimus—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0095	0.0184	CbGbCtD
Tacrolimus—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00859	0.0167	CbGbCtD
Tacrolimus—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00859	0.0167	CbGbCtD
Tacrolimus—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00824	0.016	CbGbCtD
Tacrolimus—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00799	0.0155	CbGbCtD
Tacrolimus—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00751	0.0146	CbGbCtD
Tacrolimus—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00751	0.0146	CbGbCtD
Tacrolimus—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00679	0.0132	CbGbCtD
Tacrolimus—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00679	0.0132	CbGbCtD
Tacrolimus—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00637	0.0124	CbGbCtD
Tacrolimus—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00586	0.0114	CbGbCtD
Tacrolimus—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00569	0.011	CbGbCtD
Tacrolimus—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00515	0.00998	CbGbCtD
Tacrolimus—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00515	0.00998	CbGbCtD
Tacrolimus—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00494	0.00957	CbGbCtD
Tacrolimus—ORM1—saliva—acquired immunodeficiency syndrome	0.00303	0.0535	CbGeAlD
Tacrolimus—PPP3CA—blood plasma—acquired immunodeficiency syndrome	0.00254	0.0448	CbGeAlD
Tacrolimus—ABCA5—retina—acquired immunodeficiency syndrome	0.00206	0.0363	CbGeAlD
Tacrolimus—MTOR—blood plasma—acquired immunodeficiency syndrome	0.00187	0.0331	CbGeAlD
Tacrolimus—FKBP1A—blood plasma—acquired immunodeficiency syndrome	0.00169	0.0298	CbGeAlD
Tacrolimus—PPP3CA—Initiation of transcription and translation elongation at the HIV-1 LTR—CCNT1—acquired immunodeficiency syndrome	0.00161	0.0831	CbGpPWpGaD
Tacrolimus—PPP3CA—retina—acquired immunodeficiency syndrome	0.00139	0.0245	CbGeAlD
Tacrolimus—ABCA5—blood—acquired immunodeficiency syndrome	0.00138	0.0243	CbGeAlD
Tacrolimus—ABCA5—bone marrow—acquired immunodeficiency syndrome	0.00133	0.0235	CbGeAlD
Tacrolimus—ABCA5—spinal cord—acquired immunodeficiency syndrome	0.00133	0.0234	CbGeAlD
Tacrolimus—ABCA5—vagina—acquired immunodeficiency syndrome	0.00128	0.0225	CbGeAlD
Tacrolimus—ABCA5—lung—acquired immunodeficiency syndrome	0.00121	0.0213	CbGeAlD
Tacrolimus—ABCA5—nervous system—acquired immunodeficiency syndrome	0.00112	0.0197	CbGeAlD
Tacrolimus—ABCA5—central nervous system—acquired immunodeficiency syndrome	0.00108	0.019	CbGeAlD
Tacrolimus—MTOR—retina—acquired immunodeficiency syndrome	0.00103	0.0181	CbGeAlD
Tacrolimus—PPP3CA—lymphoid tissue—acquired immunodeficiency syndrome	0.000987	0.0174	CbGeAlD
Tacrolimus—PPP3CA—digestive system—acquired immunodeficiency syndrome	0.000975	0.0172	CbGeAlD
Tacrolimus—PPP3CA—blood—acquired immunodeficiency syndrome	0.000929	0.0164	CbGeAlD
Tacrolimus—FKBP1A—retina—acquired immunodeficiency syndrome	0.000923	0.0163	CbGeAlD
Tacrolimus—MTOR—skin of body—acquired immunodeficiency syndrome	0.000901	0.0159	CbGeAlD
Tacrolimus—PPP3CA—bone marrow—acquired immunodeficiency syndrome	0.000899	0.0159	CbGeAlD
Tacrolimus—PPP3CA—spinal cord—acquired immunodeficiency syndrome	0.000895	0.0158	CbGeAlD
Tacrolimus—PPP3CA—vagina—acquired immunodeficiency syndrome	0.000861	0.0152	CbGeAlD
Tacrolimus—ABCA5—brain—acquired immunodeficiency syndrome	0.000854	0.0151	CbGeAlD
Tacrolimus—ABCA5—lymph node—acquired immunodeficiency syndrome	0.000825	0.0146	CbGeAlD
Tacrolimus—PPP3CA—lung—acquired immunodeficiency syndrome	0.000815	0.0144	CbGeAlD
Tacrolimus—FKBP1A—skin of body—acquired immunodeficiency syndrome	0.00081	0.0143	CbGeAlD
Tacrolimus—PPP3CA—nervous system—acquired immunodeficiency syndrome	0.000754	0.0133	CbGeAlD
Tacrolimus—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000734	0.013	CbGeAlD
Tacrolimus—MTOR—lymphoid tissue—acquired immunodeficiency syndrome	0.000729	0.0129	CbGeAlD
Tacrolimus—PPP3CA—central nervous system—acquired immunodeficiency syndrome	0.000726	0.0128	CbGeAlD
Tacrolimus—MTOR—digestive system—acquired immunodeficiency syndrome	0.00072	0.0127	CbGeAlD
Tacrolimus—MTOR—blood—acquired immunodeficiency syndrome	0.000686	0.0121	CbGeAlD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—CD8A—acquired immunodeficiency syndrome	0.000684	0.0354	CbGpPWpGaD
Tacrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—CCNT1—acquired immunodeficiency syndrome	0.000666	0.0344	CbGpPWpGaD
Tacrolimus—MTOR—bone marrow—acquired immunodeficiency syndrome	0.000664	0.0117	CbGeAlD
Tacrolimus—MTOR—spinal cord—acquired immunodeficiency syndrome	0.000661	0.0117	CbGeAlD
Tacrolimus—FKBP1A—lymphoid tissue—acquired immunodeficiency syndrome	0.000656	0.0116	CbGeAlD
Tacrolimus—FKBP1A—digestive system—acquired immunodeficiency syndrome	0.000648	0.0114	CbGeAlD
Tacrolimus—MTOR—vagina—acquired immunodeficiency syndrome	0.000636	0.0112	CbGeAlD
Tacrolimus—FKBP1A—blood—acquired immunodeficiency syndrome	0.000617	0.0109	CbGeAlD
Tacrolimus—MTOR—lung—acquired immunodeficiency syndrome	0.000602	0.0106	CbGeAlD
Tacrolimus—FKBP1A—bone marrow—acquired immunodeficiency syndrome	0.000597	0.0105	CbGeAlD
Tacrolimus—FKBP1A—spinal cord—acquired immunodeficiency syndrome	0.000595	0.0105	CbGeAlD
Tacrolimus—PPP3CA—brain—acquired immunodeficiency syndrome	0.000577	0.0102	CbGeAlD
Tacrolimus—FKBP1A—vagina—acquired immunodeficiency syndrome	0.000572	0.0101	CbGeAlD
Tacrolimus—MTOR—nervous system—acquired immunodeficiency syndrome	0.000557	0.00984	CbGeAlD
Tacrolimus—PPP3CA—lymph node—acquired immunodeficiency syndrome	0.000557	0.00984	CbGeAlD
Tacrolimus—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000551	0.00972	CbGeAlD
Tacrolimus—FKBP1A—lung—acquired immunodeficiency syndrome	0.000541	0.00956	CbGeAlD
Tacrolimus—MTOR—central nervous system—acquired immunodeficiency syndrome	0.000536	0.00947	CbGeAlD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—acquired immunodeficiency syndrome	0.000536	0.0277	CbGpPWpGaD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CSF2—acquired immunodeficiency syndrome	0.00053	0.0274	CbGpPWpGaD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL4—acquired immunodeficiency syndrome	0.000522	0.027	CbGpPWpGaD
Tacrolimus—FKBP1A—nervous system—acquired immunodeficiency syndrome	0.000501	0.00885	CbGeAlD
Tacrolimus—ORM1—blood—acquired immunodeficiency syndrome	0.000483	0.00853	CbGeAlD
Tacrolimus—FKBP1A—central nervous system—acquired immunodeficiency syndrome	0.000483	0.00852	CbGeAlD
Tacrolimus—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000468	0.00826	CbGeAlD
Tacrolimus—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000466	0.00822	CbGeAlD
Tacrolimus—PPP3CA—BCR signaling pathway—CD79A—acquired immunodeficiency syndrome	0.000434	0.0225	CbGpPWpGaD
Tacrolimus—MTOR—brain—acquired immunodeficiency syndrome	0.000426	0.00752	CbGeAlD
Tacrolimus—ORM1—lung—acquired immunodeficiency syndrome	0.000424	0.00748	CbGeAlD
Tacrolimus—MTOR—lymph node—acquired immunodeficiency syndrome	0.000412	0.00727	CbGeAlD
Tacrolimus—ORM1—nervous system—acquired immunodeficiency syndrome	0.000392	0.00693	CbGeAlD
Tacrolimus—ALB—FOXA2 and FOXA3 transcription factor networks—TAT—acquired immunodeficiency syndrome	0.000392	0.0203	CbGpPWpGaD
Tacrolimus—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00039	0.00688	CbGeAlD
Tacrolimus—FKBP1A—brain—acquired immunodeficiency syndrome	0.000383	0.00676	CbGeAlD
Tacrolimus—MTOR—IL12-mediated signaling events—CCL4—acquired immunodeficiency syndrome	0.000383	0.0198	CbGpPWpGaD
Tacrolimus—ORM1—central nervous system—acquired immunodeficiency syndrome	0.000378	0.00667	CbGeAlD
Tacrolimus—FKBP1A—lymph node—acquired immunodeficiency syndrome	0.00037	0.00654	CbGeAlD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—IL2—acquired immunodeficiency syndrome	0.000361	0.0187	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000316	0.0163	CbGpPWpGaD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—acquired immunodeficiency syndrome	0.000315	0.0163	CbGpPWpGaD
Tacrolimus—ORM1—lymph node—acquired immunodeficiency syndrome	0.00029	0.00512	CbGeAlD
Tacrolimus—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000282	0.00498	CbGeAlD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—acquired immunodeficiency syndrome	0.00028	0.0145	CbGpPWpGaD
Tacrolimus—CYP3A5—blood—acquired immunodeficiency syndrome	0.000269	0.00475	CbGeAlD
Tacrolimus—ALB—brain—acquired immunodeficiency syndrome	0.000263	0.00464	CbGeAlD
Tacrolimus—MTOR—IL12-mediated signaling events—CCL3—acquired immunodeficiency syndrome	0.000262	0.0135	CbGpPWpGaD
Tacrolimus—ALB—lymph node—acquired immunodeficiency syndrome	0.000254	0.00449	CbGeAlD
Tacrolimus—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000249	0.0044	CbGeAlD
Tacrolimus—FKBP1A—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000245	0.0127	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000238	0.0123	CbGpPWpGaD
Tacrolimus—CYP3A5—lung—acquired immunodeficiency syndrome	0.000236	0.00416	CbGeAlD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.000219	0.0113	CbGpPWpGaD
Tacrolimus—ABCB1—retina—acquired immunodeficiency syndrome	0.000213	0.00377	CbGeAlD
Tacrolimus—PPP3CA—Amyotrophic lateral sclerosis (ALS)—TNF—acquired immunodeficiency syndrome	0.000212	0.011	CbGpPWpGaD
Tacrolimus—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000212	0.00374	CbGeAlD
Tacrolimus—CYP3A4—blood—acquired immunodeficiency syndrome	0.000202	0.00356	CbGeAlD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—acquired immunodeficiency syndrome	0.000192	0.00992	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CXCL12—acquired immunodeficiency syndrome	0.00017	0.00879	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CXCR4—acquired immunodeficiency syndrome	0.00017	0.00879	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.00017	0.00878	CbGpPWpGaD
Tacrolimus—PPP3CA—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	0.000168	0.00868	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—CCL3—acquired immunodeficiency syndrome	0.000167	0.00865	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000167	0.00865	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD8A—acquired immunodeficiency syndrome	0.000167	0.00863	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000164	0.0085	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000164	0.0085	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000164	0.00849	CbGpPWpGaD
Tacrolimus—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000164	0.00289	CbGeAlD
Tacrolimus—MTOR—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.00016	0.00827	CbGpPWpGaD
Tacrolimus—PPP3CA—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	0.000158	0.00816	CbGpPWpGaD
Tacrolimus—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000158	0.00278	CbGeAlD
Tacrolimus—MTOR—IL12-mediated signaling events—CCR5—acquired immunodeficiency syndrome	0.000152	0.00789	CbGpPWpGaD
Tacrolimus—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000152	0.00268	CbGeAlD
Tacrolimus—ABCB1—digestive system—acquired immunodeficiency syndrome	0.00015	0.00265	CbGeAlD
Tacrolimus—MTOR—Type II diabetes mellitus—TNF—acquired immunodeficiency syndrome	0.000143	0.00741	CbGpPWpGaD
Tacrolimus—ABCB1—blood—acquired immunodeficiency syndrome	0.000143	0.00252	CbGeAlD
Tacrolimus—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000138	0.00244	CbGeAlD
Tacrolimus—PPP3CA—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.000138	0.00712	CbGpPWpGaD
Tacrolimus—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000138	0.00243	CbGeAlD
Tacrolimus—ABCB1—vagina—acquired immunodeficiency syndrome	0.000132	0.00234	CbGeAlD
Tacrolimus—PPP3CA—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000132	0.00685	CbGpPWpGaD
Tacrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—acquired immunodeficiency syndrome	0.00013	0.00671	CbGpPWpGaD
Tacrolimus—MTOR—IFN-gamma pathway—IFNG—acquired immunodeficiency syndrome	0.000129	0.0067	CbGpPWpGaD
Tacrolimus—ABCB1—lung—acquired immunodeficiency syndrome	0.000125	0.00221	CbGeAlD
Tacrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—acquired immunodeficiency syndrome	0.000124	0.00642	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—TNF—acquired immunodeficiency syndrome	0.000118	0.00611	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.000118	0.00608	CbGpPWpGaD
Tacrolimus—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000116	0.00205	CbGeAlD
Tacrolimus—PPP3CA—Innate Immune System—MBL2—acquired immunodeficiency syndrome	0.000113	0.00585	CbGpPWpGaD
Tacrolimus—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	0.000112	0.00582	CbGpPWpGaD
Tacrolimus—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000112	0.00197	CbGeAlD
Tacrolimus—MTOR—Signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	0.000106	0.00547	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000103	0.00531	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000101	0.00524	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.0001	0.0052	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IFNG—acquired immunodeficiency syndrome	9.91e-05	0.00513	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.87e-05	0.00511	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD4—acquired immunodeficiency syndrome	9.57e-05	0.00495	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	9.47e-05	0.0049	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	9.15e-05	0.00474	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	9.12e-05	0.00472	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—IFNG—acquired immunodeficiency syndrome	8.97e-05	0.00464	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	8.87e-05	0.00459	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	8.87e-05	0.00459	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CCR2—acquired immunodeficiency syndrome	8.87e-05	0.00459	CbGpPWpGaD
Tacrolimus—ABCB1—brain—acquired immunodeficiency syndrome	8.86e-05	0.00156	CbGeAlD
Tacrolimus—MTOR—IL12-mediated signaling events—IL2—acquired immunodeficiency syndrome	8.81e-05	0.00456	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CD4—acquired immunodeficiency syndrome	8.66e-05	0.00448	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	8.56e-05	0.00443	CbGpPWpGaD
Tacrolimus—ABCB1—lymph node—acquired immunodeficiency syndrome	8.56e-05	0.00151	CbGeAlD
Tacrolimus—PPP3CA—Disease—CCNT1—acquired immunodeficiency syndrome	8.54e-05	0.00442	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—CD79A—acquired immunodeficiency syndrome	8.05e-05	0.00417	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ACTG1—acquired immunodeficiency syndrome	8.02e-05	0.00415	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	7.99e-05	0.00413	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	7.97e-05	0.00412	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—APOBEC3G—acquired immunodeficiency syndrome	7.79e-05	0.00403	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	7.68e-05	0.00398	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.65e-05	0.00396	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	7.47e-05	0.00386	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CD4—acquired immunodeficiency syndrome	7.31e-05	0.00378	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	6.91e-05	0.00358	CbGpPWpGaD
Tacrolimus—MTOR—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	6.88e-05	0.00356	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	6.75e-05	0.00349	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	6.64e-05	0.00344	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CCNT1—acquired immunodeficiency syndrome	6.62e-05	0.00343	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—MBL2—acquired immunodeficiency syndrome	6.59e-05	0.00341	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	6.46e-05	0.00334	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	6.33e-05	0.00328	CbGpPWpGaD
Tacrolimus—MTOR—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	6.29e-05	0.00326	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.25e-05	0.00324	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	6.01e-05	0.00311	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	6e-05	0.00311	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.98e-05	0.00309	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.98e-05	0.00309	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	5.82e-05	0.00301	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	5.82e-05	0.00301	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	5.66e-05	0.00293	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.65e-05	0.00293	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	5.55e-05	0.00287	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	5.54e-05	0.00287	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.41e-05	0.0028	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	5.36e-05	0.00277	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.32e-05	0.00275	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.32e-05	0.00275	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CCR2—acquired immunodeficiency syndrome	5.17e-05	0.00267	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	5e-05	0.00259	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—MBL2—acquired immunodeficiency syndrome	4.93e-05	0.00255	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	4.9e-05	0.00254	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFNA1—acquired immunodeficiency syndrome	4.65e-05	0.00241	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.64e-05	0.0024	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.64e-05	0.0024	CbGpPWpGaD
Tacrolimus—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	4.52e-05	0.000227	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	4.52e-05	0.000227	CcSEcCtD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	4.52e-05	0.00234	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD79A—acquired immunodeficiency syndrome	4.52e-05	0.00234	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	4.51e-05	0.00234	CbGpPWpGaD
Tacrolimus—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	4.51e-05	0.000226	CcSEcCtD
Tacrolimus—Pruritus—Abacavir—acquired immunodeficiency syndrome	4.5e-05	0.000226	CcSEcCtD
Tacrolimus—Fatigue—Indinavir—acquired immunodeficiency syndrome	4.5e-05	0.000226	CcSEcCtD
Tacrolimus—Anorexia—Delavirdine—acquired immunodeficiency syndrome	4.5e-05	0.000226	CcSEcCtD
Tacrolimus—Discomfort—Ritonavir—acquired immunodeficiency syndrome	4.5e-05	0.000226	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	4.49e-05	0.000226	CcSEcCtD
Tacrolimus—Cough—Saquinavir—acquired immunodeficiency syndrome	4.49e-05	0.000226	CcSEcCtD
Tacrolimus—PPP3CA—Disease—CXCR4—acquired immunodeficiency syndrome	4.49e-05	0.00232	CbGpPWpGaD
Tacrolimus—Pain—Indinavir—acquired immunodeficiency syndrome	4.46e-05	0.000224	CcSEcCtD
Tacrolimus—Constipation—Indinavir—acquired immunodeficiency syndrome	4.46e-05	0.000224	CcSEcCtD
Tacrolimus—Insomnia—Efavirenz—acquired immunodeficiency syndrome	4.46e-05	0.000224	CcSEcCtD
Tacrolimus—Urticaria—Zidovudine—acquired immunodeficiency syndrome	4.46e-05	0.000224	CcSEcCtD
Tacrolimus—Convulsion—Saquinavir—acquired immunodeficiency syndrome	4.46e-05	0.000224	CcSEcCtD
Tacrolimus—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	4.45e-05	0.000224	CcSEcCtD
Tacrolimus—Hypertension—Saquinavir—acquired immunodeficiency syndrome	4.44e-05	0.000223	CcSEcCtD
Tacrolimus—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	4.44e-05	0.000223	CcSEcCtD
Tacrolimus—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	4.44e-05	0.000223	CcSEcCtD
Tacrolimus—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	4.43e-05	0.000223	CcSEcCtD
Tacrolimus—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	4.43e-05	0.000223	CcSEcCtD
Tacrolimus—Malaise—Lamivudine—acquired immunodeficiency syndrome	4.43e-05	0.000222	CcSEcCtD
Tacrolimus—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	4.42e-05	0.000222	CcSEcCtD
Tacrolimus—Nausea—Didanosine—acquired immunodeficiency syndrome	4.42e-05	0.000222	CcSEcCtD
Tacrolimus—Vertigo—Lamivudine—acquired immunodeficiency syndrome	4.41e-05	0.000222	CcSEcCtD
Tacrolimus—Hypotension—Delavirdine—acquired immunodeficiency syndrome	4.41e-05	0.000222	CcSEcCtD
Tacrolimus—Syncope—Lamivudine—acquired immunodeficiency syndrome	4.4e-05	0.000221	CcSEcCtD
Tacrolimus—Confusional state—Ritonavir—acquired immunodeficiency syndrome	4.4e-05	0.000221	CcSEcCtD
Tacrolimus—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	4.4e-05	0.000221	CcSEcCtD
Tacrolimus—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	4.39e-05	0.000221	CcSEcCtD
Tacrolimus—Somnolence—Efavirenz—acquired immunodeficiency syndrome	4.38e-05	0.00022	CcSEcCtD
Tacrolimus—Chest pain—Saquinavir—acquired immunodeficiency syndrome	4.38e-05	0.00022	CcSEcCtD
Tacrolimus—Myalgia—Saquinavir—acquired immunodeficiency syndrome	4.38e-05	0.00022	CcSEcCtD
Tacrolimus—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	4.38e-05	0.00022	CcSEcCtD
Tacrolimus—MTOR—Disease—APOBEC3G—acquired immunodeficiency syndrome	4.38e-05	0.00227	CbGpPWpGaD
Tacrolimus—Anxiety—Saquinavir—acquired immunodeficiency syndrome	4.37e-05	0.000219	CcSEcCtD
Tacrolimus—Oedema—Ritonavir—acquired immunodeficiency syndrome	4.36e-05	0.000219	CcSEcCtD
Tacrolimus—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	4.35e-05	0.000219	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	4.35e-05	0.000219	CcSEcCtD
Tacrolimus—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	4.34e-05	0.000218	CcSEcCtD
Tacrolimus—Discomfort—Saquinavir—acquired immunodeficiency syndrome	4.33e-05	0.000218	CcSEcCtD
Tacrolimus—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	4.31e-05	0.000217	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.3e-05	0.00223	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.3e-05	0.00223	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	4.3e-05	0.000216	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	4.3e-05	0.000216	CcSEcCtD
Tacrolimus—Shock—Ritonavir—acquired immunodeficiency syndrome	4.29e-05	0.000216	CcSEcCtD
Tacrolimus—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	4.29e-05	0.000215	CcSEcCtD
Tacrolimus—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	4.28e-05	0.000215	CcSEcCtD
Tacrolimus—Cough—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000215	CcSEcCtD
Tacrolimus—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	4.28e-05	0.000215	CcSEcCtD
Tacrolimus—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	4.28e-05	0.000215	CcSEcCtD
Tacrolimus—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	4.27e-05	0.000215	CcSEcCtD
Tacrolimus—Dizziness—Stavudine—acquired immunodeficiency syndrome	4.27e-05	0.000215	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	4.27e-05	0.000215	CcSEcCtD
Tacrolimus—Insomnia—Delavirdine—acquired immunodeficiency syndrome	4.27e-05	0.000214	CcSEcCtD
Tacrolimus—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	4.26e-05	0.000214	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	4.26e-05	0.000214	CcSEcCtD
Tacrolimus—Convulsion—Lamivudine—acquired immunodeficiency syndrome	4.25e-05	0.000214	CcSEcCtD
Tacrolimus—Vomiting—Nevirapine—acquired immunodeficiency syndrome	4.25e-05	0.000214	CcSEcCtD
Tacrolimus—Fatigue—Efavirenz—acquired immunodeficiency syndrome	4.25e-05	0.000214	CcSEcCtD
Tacrolimus—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	4.24e-05	0.000213	CcSEcCtD
Tacrolimus—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	4.24e-05	0.000213	CcSEcCtD
Tacrolimus—Confusional state—Saquinavir—acquired immunodeficiency syndrome	4.23e-05	0.000213	CcSEcCtD
Tacrolimus—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	4.22e-05	0.000212	CcSEcCtD
Tacrolimus—Pain—Efavirenz—acquired immunodeficiency syndrome	4.22e-05	0.000212	CcSEcCtD
Tacrolimus—Constipation—Efavirenz—acquired immunodeficiency syndrome	4.22e-05	0.000212	CcSEcCtD
Tacrolimus—Rash—Nevirapine—acquired immunodeficiency syndrome	4.22e-05	0.000212	CcSEcCtD
Tacrolimus—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	4.21e-05	0.000212	CcSEcCtD
Tacrolimus—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	4.21e-05	0.000211	CcSEcCtD
Tacrolimus—Dizziness—Abacavir—acquired immunodeficiency syndrome	4.21e-05	0.000211	CcSEcCtD
Tacrolimus—Oedema—Saquinavir—acquired immunodeficiency syndrome	4.2e-05	0.000211	CcSEcCtD
Tacrolimus—Somnolence—Delavirdine—acquired immunodeficiency syndrome	4.19e-05	0.000211	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.19e-05	0.00217	CbGpPWpGaD
Tacrolimus—Headache—Nevirapine—acquired immunodeficiency syndrome	4.19e-05	0.000211	CcSEcCtD
Tacrolimus—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	4.18e-05	0.00021	CcSEcCtD
Tacrolimus—Chest pain—Lamivudine—acquired immunodeficiency syndrome	4.18e-05	0.00021	CcSEcCtD
Tacrolimus—Myalgia—Lamivudine—acquired immunodeficiency syndrome	4.18e-05	0.00021	CcSEcCtD
Tacrolimus—Infection—Saquinavir—acquired immunodeficiency syndrome	4.17e-05	0.00021	CcSEcCtD
Tacrolimus—Anxiety—Lamivudine—acquired immunodeficiency syndrome	4.16e-05	0.000209	CcSEcCtD
Tacrolimus—Anorexia—Ritonavir—acquired immunodeficiency syndrome	4.16e-05	0.000209	CcSEcCtD
Tacrolimus—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	4.15e-05	0.000209	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	4.15e-05	0.000209	CcSEcCtD
Tacrolimus—Urticaria—Indinavir—acquired immunodeficiency syndrome	4.15e-05	0.000208	CcSEcCtD
Tacrolimus—Shock—Saquinavir—acquired immunodeficiency syndrome	4.13e-05	0.000208	CcSEcCtD
Tacrolimus—Discomfort—Lamivudine—acquired immunodeficiency syndrome	4.13e-05	0.000208	CcSEcCtD
Tacrolimus—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	4.13e-05	0.000207	CcSEcCtD
Tacrolimus—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	4.13e-05	0.000207	CcSEcCtD
Tacrolimus—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	4.12e-05	0.000207	CcSEcCtD
Tacrolimus—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	4.12e-05	0.000207	CcSEcCtD
Tacrolimus—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	4.11e-05	0.000207	CcSEcCtD
Tacrolimus—Vomiting—Stavudine—acquired immunodeficiency syndrome	4.1e-05	0.000206	CcSEcCtD
Tacrolimus—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	4.1e-05	0.000206	CcSEcCtD
Tacrolimus—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	4.09e-05	0.000205	CcSEcCtD
Tacrolimus—Rash—Nelfinavir—acquired immunodeficiency syndrome	4.08e-05	0.000205	CcSEcCtD
Tacrolimus—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	4.08e-05	0.000205	CcSEcCtD
Tacrolimus—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	4.08e-05	0.000205	CcSEcCtD
Tacrolimus—Hypotension—Ritonavir—acquired immunodeficiency syndrome	4.08e-05	0.000205	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	4.07e-05	0.000205	CcSEcCtD
Tacrolimus—Rash—Stavudine—acquired immunodeficiency syndrome	4.07e-05	0.000205	CcSEcCtD
Tacrolimus—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.07e-05	0.000204	CcSEcCtD
Tacrolimus—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.07e-05	0.000204	CcSEcCtD
Tacrolimus—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	4.06e-05	0.000204	CcSEcCtD
Tacrolimus—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	4.06e-05	0.000204	CcSEcCtD
Tacrolimus—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.06e-05	0.000204	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.04e-05	0.00209	CbGpPWpGaD
Tacrolimus—Headache—Stavudine—acquired immunodeficiency syndrome	4.04e-05	0.000203	CcSEcCtD
Tacrolimus—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.04e-05	0.000203	CcSEcCtD
Tacrolimus—Confusional state—Lamivudine—acquired immunodeficiency syndrome	4.04e-05	0.000203	CcSEcCtD
Tacrolimus—Pain—Delavirdine—acquired immunodeficiency syndrome	4.03e-05	0.000203	CcSEcCtD
Tacrolimus—Constipation—Delavirdine—acquired immunodeficiency syndrome	4.03e-05	0.000203	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.03e-05	0.000203	CcSEcCtD
Tacrolimus—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.03e-05	0.000202	CcSEcCtD
Tacrolimus—Rash—Abacavir—acquired immunodeficiency syndrome	4.01e-05	0.000202	CcSEcCtD
Tacrolimus—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	4.01e-05	0.00208	CbGpPWpGaD
Tacrolimus—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.01e-05	0.000201	CcSEcCtD
Tacrolimus—Oedema—Lamivudine—acquired immunodeficiency syndrome	4.01e-05	0.000201	CcSEcCtD
Tacrolimus—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	4.01e-05	0.000201	CcSEcCtD
Tacrolimus—Anorexia—Saquinavir—acquired immunodeficiency syndrome	4e-05	0.000201	CcSEcCtD
Tacrolimus—Headache—Abacavir—acquired immunodeficiency syndrome	3.98e-05	0.0002	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.98e-05	0.00206	CbGpPWpGaD
Tacrolimus—Infection—Lamivudine—acquired immunodeficiency syndrome	3.98e-05	0.0002	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	3.97e-05	0.0002	CcSEcCtD
Tacrolimus—Nausea—Nevirapine—acquired immunodeficiency syndrome	3.97e-05	0.0002	CcSEcCtD
Tacrolimus—Pruritus—Zidovudine—acquired immunodeficiency syndrome	3.97e-05	0.0002	CcSEcCtD
Tacrolimus—Insomnia—Ritonavir—acquired immunodeficiency syndrome	3.95e-05	0.000198	CcSEcCtD
Tacrolimus—Shock—Lamivudine—acquired immunodeficiency syndrome	3.94e-05	0.000198	CcSEcCtD
Tacrolimus—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	3.93e-05	0.000197	CcSEcCtD
Tacrolimus—Hypotension—Saquinavir—acquired immunodeficiency syndrome	3.92e-05	0.000197	CcSEcCtD
Tacrolimus—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	3.92e-05	0.000197	CcSEcCtD
Tacrolimus—MTOR—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	3.92e-05	0.00203	CbGpPWpGaD
Tacrolimus—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	3.92e-05	0.000197	CcSEcCtD
Tacrolimus—Urticaria—Efavirenz—acquired immunodeficiency syndrome	3.92e-05	0.000197	CcSEcCtD
Tacrolimus—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	3.9e-05	0.000196	CcSEcCtD
Tacrolimus—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	3.9e-05	0.000196	CcSEcCtD
Tacrolimus—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	3.89e-05	0.000196	CcSEcCtD
Tacrolimus—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	3.89e-05	0.000196	CcSEcCtD
Tacrolimus—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	3.89e-05	0.000195	CcSEcCtD
Tacrolimus—Somnolence—Ritonavir—acquired immunodeficiency syndrome	3.88e-05	0.000195	CcSEcCtD
Tacrolimus—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	3.87e-05	0.000195	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—CCR2—acquired immunodeficiency syndrome	3.87e-05	0.002	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	3.86e-05	0.000194	CcSEcCtD
Tacrolimus—Nausea—Nelfinavir—acquired immunodeficiency syndrome	3.85e-05	0.000193	CcSEcCtD
Tacrolimus—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	3.84e-05	0.000193	CcSEcCtD
Tacrolimus—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	3.84e-05	0.000193	CcSEcCtD
Tacrolimus—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	3.84e-05	0.000193	CcSEcCtD
Tacrolimus—Nausea—Stavudine—acquired immunodeficiency syndrome	3.83e-05	0.000193	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	3.83e-05	0.000192	CcSEcCtD
Tacrolimus—Anorexia—Lamivudine—acquired immunodeficiency syndrome	3.82e-05	0.000192	CcSEcCtD
Tacrolimus—MTOR—IRS-related events—IL6—acquired immunodeficiency syndrome	3.81e-05	0.00197	CbGpPWpGaD
Tacrolimus—Insomnia—Saquinavir—acquired immunodeficiency syndrome	3.8e-05	0.000191	CcSEcCtD
Tacrolimus—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	3.79e-05	0.000191	CcSEcCtD
Tacrolimus—Nausea—Abacavir—acquired immunodeficiency syndrome	3.78e-05	0.00019	CcSEcCtD
Tacrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	3.78e-05	0.00195	CbGpPWpGaD
Tacrolimus—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	3.77e-05	0.00019	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	3.77e-05	0.000189	CcSEcCtD
Tacrolimus—Fatigue—Ritonavir—acquired immunodeficiency syndrome	3.76e-05	0.000189	CcSEcCtD
Tacrolimus—Urticaria—Delavirdine—acquired immunodeficiency syndrome	3.75e-05	0.000188	CcSEcCtD
Tacrolimus—Asthenia—Indinavir—acquired immunodeficiency syndrome	3.74e-05	0.000188	CcSEcCtD
Tacrolimus—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	3.74e-05	0.000188	CcSEcCtD
Tacrolimus—Hypotension—Lamivudine—acquired immunodeficiency syndrome	3.74e-05	0.000188	CcSEcCtD
Tacrolimus—Somnolence—Saquinavir—acquired immunodeficiency syndrome	3.73e-05	0.000188	CcSEcCtD
Tacrolimus—Pain—Ritonavir—acquired immunodeficiency syndrome	3.73e-05	0.000188	CcSEcCtD
Tacrolimus—Constipation—Ritonavir—acquired immunodeficiency syndrome	3.73e-05	0.000188	CcSEcCtD
Tacrolimus—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	3.73e-05	0.000187	CcSEcCtD
Tacrolimus—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	3.73e-05	0.000187	CcSEcCtD
Tacrolimus—MTOR—Disease—CCNT1—acquired immunodeficiency syndrome	3.72e-05	0.00193	CbGpPWpGaD
Tacrolimus—Dizziness—Zidovudine—acquired immunodeficiency syndrome	3.71e-05	0.000187	CcSEcCtD
Tacrolimus—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	3.7e-05	0.000186	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.69e-05	0.00191	CbGpPWpGaD
Tacrolimus—Pruritus—Indinavir—acquired immunodeficiency syndrome	3.69e-05	0.000186	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—CD40LG—acquired immunodeficiency syndrome	3.68e-05	0.00191	CbGpPWpGaD
Tacrolimus—MTOR—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	3.68e-05	0.0019	CbGpPWpGaD
Tacrolimus—MTOR—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	3.68e-05	0.0019	CbGpPWpGaD
Tacrolimus—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	3.65e-05	0.000183	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	3.65e-05	0.000183	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.64e-05	0.00189	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CSF2—acquired immunodeficiency syndrome	3.64e-05	0.00188	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD8A—acquired immunodeficiency syndrome	3.64e-05	0.00188	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	3.63e-05	0.000183	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	3.63e-05	0.000182	CcSEcCtD
Tacrolimus—Insomnia—Lamivudine—acquired immunodeficiency syndrome	3.62e-05	0.000182	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—TAT—acquired immunodeficiency syndrome	3.62e-05	0.00187	CbGpPWpGaD
Tacrolimus—Fatigue—Saquinavir—acquired immunodeficiency syndrome	3.62e-05	0.000182	CcSEcCtD
Tacrolimus—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	3.6e-05	0.000181	CcSEcCtD
Tacrolimus—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	3.6e-05	0.000181	CcSEcCtD
Tacrolimus—Constipation—Saquinavir—acquired immunodeficiency syndrome	3.59e-05	0.000181	CcSEcCtD
Tacrolimus—Pain—Saquinavir—acquired immunodeficiency syndrome	3.59e-05	0.000181	CcSEcCtD
Tacrolimus—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	3.59e-05	0.00186	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.59e-05	0.00186	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	3.58e-05	0.00186	CbGpPWpGaD
Tacrolimus—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	3.57e-05	0.00018	CcSEcCtD
Tacrolimus—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	3.57e-05	0.000179	CcSEcCtD
Tacrolimus—Vomiting—Zidovudine—acquired immunodeficiency syndrome	3.57e-05	0.000179	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	3.57e-05	0.000179	CcSEcCtD
Tacrolimus—Somnolence—Lamivudine—acquired immunodeficiency syndrome	3.56e-05	0.000179	CcSEcCtD
Tacrolimus—Rash—Zidovudine—acquired immunodeficiency syndrome	3.54e-05	0.000178	CcSEcCtD
Tacrolimus—Asthenia—Efavirenz—acquired immunodeficiency syndrome	3.54e-05	0.000178	CcSEcCtD
Tacrolimus—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	3.53e-05	0.000178	CcSEcCtD
Tacrolimus—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	3.53e-05	0.000177	CcSEcCtD
Tacrolimus—Headache—Zidovudine—acquired immunodeficiency syndrome	3.52e-05	0.000177	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—HLA-B—acquired immunodeficiency syndrome	3.5e-05	0.00181	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ACTG1—acquired immunodeficiency syndrome	3.5e-05	0.00181	CbGpPWpGaD
Tacrolimus—Pruritus—Efavirenz—acquired immunodeficiency syndrome	3.49e-05	0.000175	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	3.48e-05	0.0018	CbGpPWpGaD
Tacrolimus—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.000175	CcSEcCtD
Tacrolimus—FKBP1A—Disease—CXCR4—acquired immunodeficiency syndrome	3.48e-05	0.0018	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	3.48e-05	0.000175	CcSEcCtD
Tacrolimus—Urticaria—Ritonavir—acquired immunodeficiency syndrome	3.47e-05	0.000174	CcSEcCtD
Tacrolimus—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	3.46e-05	0.000174	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	3.46e-05	0.000174	CcSEcCtD
Tacrolimus—Fatigue—Lamivudine—acquired immunodeficiency syndrome	3.45e-05	0.000174	CcSEcCtD
Tacrolimus—Dizziness—Indinavir—acquired immunodeficiency syndrome	3.45e-05	0.000173	CcSEcCtD
Tacrolimus—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	3.45e-05	0.000173	CcSEcCtD
Tacrolimus—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	3.45e-05	0.000173	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	3.43e-05	0.000173	CcSEcCtD
Tacrolimus—Constipation—Lamivudine—acquired immunodeficiency syndrome	3.43e-05	0.000172	CcSEcCtD
Tacrolimus—Pain—Lamivudine—acquired immunodeficiency syndrome	3.43e-05	0.000172	CcSEcCtD
Tacrolimus—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	3.42e-05	0.00177	CbGpPWpGaD
Tacrolimus—Asthenia—Delavirdine—acquired immunodeficiency syndrome	3.38e-05	0.00017	CcSEcCtD
Tacrolimus—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	3.37e-05	0.00017	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.34e-05	0.00173	CbGpPWpGaD
Tacrolimus—Pruritus—Delavirdine—acquired immunodeficiency syndrome	3.34e-05	0.000168	CcSEcCtD
Tacrolimus—Urticaria—Saquinavir—acquired immunodeficiency syndrome	3.34e-05	0.000168	CcSEcCtD
Tacrolimus—Nausea—Zidovudine—acquired immunodeficiency syndrome	3.33e-05	0.000168	CcSEcCtD
Tacrolimus—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	3.32e-05	0.000167	CcSEcCtD
Tacrolimus—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	3.32e-05	0.000167	CcSEcCtD
Tacrolimus—Vomiting—Indinavir—acquired immunodeficiency syndrome	3.32e-05	0.000167	CcSEcCtD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	3.31e-05	0.00171	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	3.3e-05	0.000166	CcSEcCtD
Tacrolimus—Rash—Indinavir—acquired immunodeficiency syndrome	3.29e-05	0.000165	CcSEcCtD
Tacrolimus—Dermatitis—Indinavir—acquired immunodeficiency syndrome	3.29e-05	0.000165	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	3.28e-05	0.000165	CcSEcCtD
Tacrolimus—Headache—Indinavir—acquired immunodeficiency syndrome	3.27e-05	0.000164	CcSEcCtD
Tacrolimus—Dizziness—Efavirenz—acquired immunodeficiency syndrome	3.26e-05	0.000164	CcSEcCtD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	3.26e-05	0.00169	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	3.25e-05	0.00168	CbGpPWpGaD
Tacrolimus—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.23e-05	0.000162	CcSEcCtD
Tacrolimus—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	3.21e-05	0.000162	CcSEcCtD
Tacrolimus—Urticaria—Lamivudine—acquired immunodeficiency syndrome	3.18e-05	0.00016	CcSEcCtD
Tacrolimus—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.17e-05	0.000159	CcSEcCtD
Tacrolimus—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.17e-05	0.000159	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.14e-05	0.00163	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.14e-05	0.00163	CbGpPWpGaD
Tacrolimus—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.14e-05	0.000158	CcSEcCtD
Tacrolimus—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.13e-05	0.000157	CcSEcCtD
Tacrolimus—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.12e-05	0.000157	CcSEcCtD
Tacrolimus—Rash—Efavirenz—acquired immunodeficiency syndrome	3.11e-05	0.000156	CcSEcCtD
Tacrolimus—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.11e-05	0.000156	CcSEcCtD
Tacrolimus—Nausea—Indinavir—acquired immunodeficiency syndrome	3.1e-05	0.000156	CcSEcCtD
Tacrolimus—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.09e-05	0.000156	CcSEcCtD
Tacrolimus—Headache—Efavirenz—acquired immunodeficiency syndrome	3.09e-05	0.000155	CcSEcCtD
Tacrolimus—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.09e-05	0.000155	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—AGPS—acquired immunodeficiency syndrome	3.08e-05	0.00159	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	3.08e-05	0.00159	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CCR5—acquired immunodeficiency syndrome	3.07e-05	0.00159	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	3.06e-05	0.00158	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	3.04e-05	0.00157	CbGpPWpGaD
Tacrolimus—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.01e-05	0.000151	CcSEcCtD
Tacrolimus—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3e-05	0.000151	CcSEcCtD
Tacrolimus—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	2.98e-05	0.00015	CcSEcCtD
Tacrolimus—Rash—Delavirdine—acquired immunodeficiency syndrome	2.97e-05	0.00015	CcSEcCtD
Tacrolimus—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	2.97e-05	0.000149	CcSEcCtD
Tacrolimus—Pruritus—Saquinavir—acquired immunodeficiency syndrome	2.97e-05	0.000149	CcSEcCtD
Tacrolimus—Headache—Delavirdine—acquired immunodeficiency syndrome	2.96e-05	0.000149	CcSEcCtD
Tacrolimus—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	2.95e-05	0.000148	CcSEcCtD
Tacrolimus—Nausea—Efavirenz—acquired immunodeficiency syndrome	2.93e-05	0.000147	CcSEcCtD
Tacrolimus—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	2.92e-05	0.00151	CbGpPWpGaD
Tacrolimus—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	2.9e-05	0.0015	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.89e-05	0.00149	CbGpPWpGaD
Tacrolimus—Dizziness—Ritonavir—acquired immunodeficiency syndrome	2.88e-05	0.000145	CcSEcCtD
Tacrolimus—Asthenia—Lamivudine—acquired immunodeficiency syndrome	2.87e-05	0.000144	CcSEcCtD
Tacrolimus—MTOR—Immune System—MBL2—acquired immunodeficiency syndrome	2.87e-05	0.00149	CbGpPWpGaD
Tacrolimus—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	2.87e-05	0.000144	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.86e-05	0.00148	CbGpPWpGaD
Tacrolimus—Pruritus—Lamivudine—acquired immunodeficiency syndrome	2.83e-05	0.000142	CcSEcCtD
Tacrolimus—Nausea—Delavirdine—acquired immunodeficiency syndrome	2.8e-05	0.000141	CcSEcCtD
Tacrolimus—Dizziness—Saquinavir—acquired immunodeficiency syndrome	2.78e-05	0.00014	CcSEcCtD
Tacrolimus—Vomiting—Ritonavir—acquired immunodeficiency syndrome	2.77e-05	0.000139	CcSEcCtD
Tacrolimus—Rash—Ritonavir—acquired immunodeficiency syndrome	2.75e-05	0.000138	CcSEcCtD
Tacrolimus—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	2.75e-05	0.000138	CcSEcCtD
Tacrolimus—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	2.74e-05	0.000138	CcSEcCtD
Tacrolimus—Headache—Ritonavir—acquired immunodeficiency syndrome	2.73e-05	0.000137	CcSEcCtD
Tacrolimus—Vomiting—Saquinavir—acquired immunodeficiency syndrome	2.67e-05	0.000134	CcSEcCtD
Tacrolimus—Dizziness—Lamivudine—acquired immunodeficiency syndrome	2.65e-05	0.000133	CcSEcCtD
Tacrolimus—Rash—Saquinavir—acquired immunodeficiency syndrome	2.65e-05	0.000133	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.65e-05	0.00137	CbGpPWpGaD
Tacrolimus—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	2.65e-05	0.000133	CcSEcCtD
Tacrolimus—Headache—Saquinavir—acquired immunodeficiency syndrome	2.63e-05	0.000132	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	2.62e-05	0.00136	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.62e-05	0.00135	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TAT—acquired immunodeficiency syndrome	2.62e-05	0.00135	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	2.61e-05	0.00135	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.61e-05	0.00135	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.61e-05	0.00135	CbGpPWpGaD
Tacrolimus—Nausea—Ritonavir—acquired immunodeficiency syndrome	2.59e-05	0.00013	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.59e-05	0.00134	CbGpPWpGaD
Tacrolimus—Vomiting—Lamivudine—acquired immunodeficiency syndrome	2.55e-05	0.000128	CcSEcCtD
Tacrolimus—Rash—Lamivudine—acquired immunodeficiency syndrome	2.53e-05	0.000127	CcSEcCtD
Tacrolimus—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	2.52e-05	0.000127	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.52e-05	0.0013	CbGpPWpGaD
Tacrolimus—Headache—Lamivudine—acquired immunodeficiency syndrome	2.51e-05	0.000126	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	2.5e-05	0.00129	CbGpPWpGaD
Tacrolimus—Nausea—Saquinavir—acquired immunodeficiency syndrome	2.49e-05	0.000125	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	2.46e-05	0.00127	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.44e-05	0.00126	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.44e-05	0.00126	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.39e-05	0.00124	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CCR5—acquired immunodeficiency syndrome	2.38e-05	0.00123	CbGpPWpGaD
Tacrolimus—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.38e-05	0.00012	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.36e-05	0.00122	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	2.36e-05	0.00122	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.35e-05	0.00122	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	2.35e-05	0.00122	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	2.34e-05	0.00121	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	2.33e-05	0.0012	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	2.32e-05	0.0012	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	2.32e-05	0.0012	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	2.25e-05	0.00117	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CCR2—acquired immunodeficiency syndrome	2.25e-05	0.00117	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AGPS—acquired immunodeficiency syndrome	2.23e-05	0.00115	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	2.22e-05	0.00115	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	2.18e-05	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	2.18e-05	0.00113	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.18e-05	0.00113	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IFNG—acquired immunodeficiency syndrome	2.16e-05	0.00112	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.16e-05	0.00112	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.15e-05	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.14e-05	0.00111	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.13e-05	0.0011	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.11e-05	0.00109	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD4—acquired immunodeficiency syndrome	2.09e-05	0.00108	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNA1—acquired immunodeficiency syndrome	2.03e-05	0.00105	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.97e-05	0.00102	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD79A—acquired immunodeficiency syndrome	1.97e-05	0.00102	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CXCR4—acquired immunodeficiency syndrome	1.96e-05	0.00101	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.94e-05	0.001	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD4—acquired immunodeficiency syndrome	1.93e-05	0.000999	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.93e-05	0.000999	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2—acquired immunodeficiency syndrome	1.92e-05	0.000996	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	1.92e-05	0.000992	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.9e-05	0.000984	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	1.87e-05	0.000969	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.85e-05	0.000959	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.82e-05	0.000944	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.68e-05	0.000869	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.67e-05	0.000864	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.61e-05	0.000834	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD40LG—acquired immunodeficiency syndrome	1.61e-05	0.000831	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD8A—acquired immunodeficiency syndrome	1.59e-05	0.000822	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CSF2—acquired immunodeficiency syndrome	1.59e-05	0.000822	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	1.58e-05	0.000819	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.57e-05	0.00081	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HLA-B—acquired immunodeficiency syndrome	1.53e-05	0.00079	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.53e-05	0.000789	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.5e-05	0.000778	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD4—acquired immunodeficiency syndrome	1.5e-05	0.000775	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.49e-05	0.00077	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000768	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.46e-05	0.000754	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.37e-05	0.000709	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.37e-05	0.000709	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CCR5—acquired immunodeficiency syndrome	1.34e-05	0.000694	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.24e-05	0.000644	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.24e-05	0.00064	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.22e-05	0.00063	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL6—acquired immunodeficiency syndrome	1.13e-05	0.000585	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.09e-05	0.000566	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—IL6—acquired immunodeficiency syndrome	1.04e-05	0.00054	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000539	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.03e-05	0.000535	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.03e-05	0.000531	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.64e-06	0.000499	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IFNG—acquired immunodeficiency syndrome	9.44e-06	0.000489	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.39e-06	0.000486	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—acquired immunodeficiency syndrome	9.12e-06	0.000472	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.47e-06	0.000438	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—acquired immunodeficiency syndrome	8.42e-06	0.000436	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—acquired immunodeficiency syndrome	8.39e-06	0.000434	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—acquired immunodeficiency syndrome	8.09e-06	0.000419	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	7.86e-06	0.000407	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.35e-06	0.00038	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.31e-06	0.000378	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—acquired immunodeficiency syndrome	6.31e-06	0.000327	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.67e-06	0.000293	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.42e-06	0.000281	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—acquired immunodeficiency syndrome	4.93e-06	0.000255	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	4.56e-06	0.000236	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—acquired immunodeficiency syndrome	4.55e-06	0.000236	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	3.44e-06	0.000178	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.19e-06	0.000165	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.12e-06	0.00011	CbGpPWpGaD
